Novocure Reports Second Quarter 2017 Financial Results and Provides Company Update

1,460 active patients at June 30, 2017, an increase of 64 percent from June 30, 2016, and 15 percent from March 31, 2017 Second quarter 2017 net revenues of $38.4 million, reflecting 114 percent growth versus second quarter 2016 and 10 percent growth versus first quarter 2017 ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today …

Novocure™ Announces a Phase 1b Clinical Trial to Evaluate the Safety of Marizomib and Temozolomide in Combination with Optune® as Adjuvant Therapy in Patients with Glioblastoma

This trial is the first to study Optune in combination with an investigational drug ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today a new arm for a phase 1b study to evaluate the safety of marizomib and temozolomide in combination with Optune, Novocure’s Tumor Treating Fields (TTFields) delivery system, as adjuvant treatment for patients with …

Novocure’s Optune® Now Available at More Than 600 Cancer Treatment Centers in the U.S.

Company broadens geographic reach of Optune in community setting, making therapy more accessible to patients Internationally, GBM patients can access Optune at an additional 350 medical institutions ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure™ (NASDAQ: NVCR) announced today that physicians at more than 600 cancer treatment centers in the U.S. have been certified to prescribe Optune to …

Data on Delivery of Tumor Treating Fields to be Presented at the 39th Annual International Conference of the IEEE Engineering in Medicine and Biology Society

Three oral presentations underscore Novocure’s commitment to further understanding the physical application of Tumor Treating Fields to enhance efficacy ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that three oral presentations on Tumor Treating Fields (TTFields) will be given at the 39th Annual International Conference of the IEEE Engineering in Medicine and Biology Society …